CHUL
2705, boulevard Laurier
R-1742
Québec, Québec
Canada G1V 4G2

Dernières nouvelles

Information non disponible

13 enregistrements « 1 de 2 »

Guillot M, Synnes A, Pronovost E, Qureshi M, Daboval T, Caouette G, Olivier F, Bartholomew J, Mohamed I, Massé E, Afifi J, Hendson L, Lemyre B, Luu TM, Strueby L, Cieslak Z, Yusuf K, Pelligra G, Ducruet T, Ndiaye ABKT, Angoa G, Sériès T, Piedboeuf B, Nuyt AM, Fraser W, Mâsse B, Lacaze-Masmonteil T, Lavoie PM, Marc I

Maternal High-Dose DHA Supplementation and Neurodevelopment at 18-22 Months of Preterm Children

Article de revue

Pediatrics, 150 (1), 2022.

Résumé | Liens:

Guillot M, Robitaille CA, Turner L, Pronovost E, Caouette G, Matte-Gagné C, Olivier F, Bartholomew J, Massé É, Morin A, Mohamed I, Marc I

Effects of maternal docosahexaenoic acid supplementation on brain development and neurodevelopmental outcomes of breastfed preterm neonates: protocol for a follow-up at preschool age of a randomised clinical trial (MOBYDIckPS)

Article de revue

BMJ Open, 12 (5), 2022.

Résumé | Liens:

Papenburg J, Defoy I, Masse E, Caouette G, Lebel MH

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study

Article de revue

J Pediatric Infect Dis Soc, 10 (3), 2021.

Résumé | Liens:

Papenburg J, Saleem M, Teselink J, Li A, Caouette G, Masse E, Lanctot KL

Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study

Article de revue

Pediatr Infect Dis J, 39 (8), 2020.

Résumé | Liens:

Marc I, Piedboeuf B, Lacaze-Masmonteil T, Fraser W, Masse B, Mohamed I, Qureshi M, Afifi J, Lemyre B, Caouette G, Bartholomew J, Nuyt AM, Julien P, Synnes A, Lucas M, Perreault T, Strueby L, Cieslak Z, Yusuf K, Pelligra G, Masse E, Larsen B, de Cabo C, Ruth C, Khurshid F, Lavoie PM

Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia-Free Survival in Breastfed Preterm Infants: A Randomized Clinical Trial

Article de revue

JAMA, 324 (2), 2020.

Résumé | Liens:

Olivier F, Nadeau S, Bélanger S, Julien AS, Massé E, Ali N, Caouette G, Piedboeuf B

Efficacy of minimally invasive surfactant therapy in moderate and late preterm infants: A multicentre randomized control trial

Article de revue

Paediatr Child Health, 22 (3), 2017.

Résumé | Liens:

Olivier F, Nadeau S, Caouette G, Piedboeuf B

Association between Apnea of Prematurity and Respiratory Distress Syndrome in Late Preterm Infants: An Observational Study

Article de revue

Front Pediatr, 4 , 2016.

Résumé | Liens:

Papenburg J, Hamelin ME, Ouhoummane N, Carbonneau J, Ouakki M, Raymond F, Robitaille L, Corbeil J, Caouette G, Frenette L, De Serres G, Boivin G

Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children

Article de revue

J Infect Dis, 206 (2), 2012.

Résumé | Liens:

Paes B, Mitchell I, Li A, Lanctot KL,

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)

Article de revue

Eur J Clin Microbiol Infect Dis, 31 (10), 2012.

Résumé | Liens:

Boivin G, Caouette G, Frenette L, Carbonneau J, Ouakki M, De Serres G

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab

Article de revue

J Clin Virol, 42 (1), 2008.

Résumé | Liens:

13 enregistrements « 1 de 2 »
Signaler des ajouts ou des modifications

Projets actifs

  • Maternal Omega-3 supplementation to reduce Bronchopulmonary Dysplasia in very Preterm Infants : A Randomized controlled trial (MOBYDIck trial), du 2014-07-01 au 2025-12-25

Projets terminés récemment

  • Vaccine coverage in preterm population, du 2022-03-14 au 2022-05-01
Information provenant du registre des projets de recherche de l'Université Laval